UB-311, a novel UBITh^® amyloid β peptide vaccine for mild Alzheimer's disease.

ABSTRACT:

Introduction

A novel amyloid β (Aβ) synthetic peptide vaccine (UB-311) has been evaluated in a first-in-human trial with patients of mild-to-moderate Alzheimer's disease. We describe translational research covering vaccine design, preclinical characterization, and phase-I clinical trial with supportive outcome that advances UB-311 into an ongoing phase-II trial.

Methods

UB-311 is constructed with two synthetic Aβ_1-14-targeting peptides (B-cell epitope), each linked to different helper T-cell peptide epitopes (UBITh^®) and formulated in a Th2-biased delivery system. The hAPP751 transgenic mouse model was used to perform the proof-of-concept study. Baboons and macaques were used for preclinical safety, tolerability, and immunogenicity evaluation. Patients

SUBMITTER: Wang CY 

PROVIDER: S-EPMC5651432 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature